Prognostic Stage IIA Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Prognostic Stage 2A Breast Cancer AJCC v8

DBCOND0109633 (Prognostic Stage IIA Breast Cancer AJCC v8)Not Yet Recruiting1 IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment